Clinical Trial Update: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon

View source ↗

Summary

The BETAEVAL Global study evaluates adherence to Betaferon therapy in relapsing-remitting multiple sclerosis patients using the BETACONNECT auto-injector.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Betaferon (interferon beta-1b)

Snippet

Sponsor: Bayer | Conditions: Multiple Sclerosis, Relapsing Remitting | Status: COMPLETED